Biologic approach to targeting a nicotinic receptor accessory molecule for cognit

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$656,365.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43MH094004-01
Award Id:
n/a
Agency Tracking Number:
R43MH094004
Solicitation Year:
2011
Solicitation Topic Code:
NIMH
Solicitation Number:
PA08-142
Small Business Information
2265 E. Foothill Blvd, Pasadena, CA, 91107-0000
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
825379659
Principal Investigator:
ANDREAS WALZ
(646) 326-9717
andreas.walz@ophidionbio.com
Business Contact:
ANDREAS WALX
(646) 327-9717
andreas.walz@ophidionbio.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): The proposed project details a biologic strategy for the therapeutic targeting of nicotinic receptors of the cholinergic system for the treatment of mental and neurological disorders. The cholinergic system is an important modulatory neurotransmitter system, regulating reward, learning and memory, attention, and cognitive functions. The nicotinic acetylcholine receptor, a major receptor of the cholinergic system, is regulated by modulatory accessory proteins which bind to nicotinic acetylcholine receptors and dampen their function. Biological proof of concept studies in our mouse models indicate that regulating cholinergic tone has a beneficial enhancement of complex circuits in the brain, leading to enhanced learningand memory function. In order to develop a therapeutic intervention recapitulating this cognitive enhancement, we propose to develop a biological therapeutic to enhance cholinergic tone in the brain through accessory molecules to nicotinic receptors. Because the blood brain barrier is the most challenging problem facing the delivery of the macromolecules to neurons in the brain, we propose several strategies for optimizing delivery based on peptides with demonstrated ability to deliver therapeutic candidates past the blood- brain barrier. We will couple the most efficient translocators. We will test the functional inhibition by therapeutic candidates on our established nicotinic receptor cell lines and assays. In addition, we will label potential carrier molecules to assess their blood-brain penetrability, and finally test the efficacy of candidates in vivo in our mouse models. If successful the outcome will lead to the development of a therapeutic candidate to treat cognitive and memory impairments associated with mental and neurological disorders, such as schizophrenia, Alzheimer's and Parkinson's disease, and depression. PUBLIC HEALTH RELEVANCE: This project involves the development of therapeutic interventions to treat the cognitive dysfunctionassociated with mental and neurological disorders, such as schizophrenia, Alzheimer's disease, Parkinson's disease, depression, and ADHD.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government